340450 — GC Genome Income Statement
0.000.00%
Last trade - 00:00- KR₩170bn
- KR₩127bn
- KR₩26bn
Annual income statement for GC Genome, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 24,114 | 27,292 | 25,888 |
| Cost of Revenue | |||
| Gross Profit | 10,765 | 13,697 | 11,707 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Depreciation and Amortization | |||
| Unusual Expense / Income | |||
| Total Operating Expenses | 27,349 | 27,132 | 28,247 |
| Operating Profit | -3,236 | 160 | -2,359 |
| Gain / Loss on Sale of Assets | |||
| Total Net Non Operating Interest Income / Expense | |||
| Other Net Non Operating Costs | |||
| Net Income Before Taxes | -3,874 | -815 | -1,127 |
| Provision for Income Taxes | |||
| Net Income After Taxes | -3,763 | -550 | -1,257 |
| Net Income Before Extraordinary Items | |||
| Net Income | -3,763 | -550 | -1,257 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -3,763 | -550 | -1,257 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -159 | -23.3 | -22.3 |
| Dividends per Share |